The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Pear, W. S., Miller, J. P., Xu, L., Pui, J. C., Soffer, B., Quackenbush, R. C., Pendergast, A. M., Bronson, R., Aster, J. C., Scott, M. L., et al. (1998) · Blood · doi:10.1182/blood.v92.10.3780 · Cited by 755
Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., & Talpaz, M. (2003) · Blood · doi:10.1182/blood.v101.2.690 · Cited by 663
Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., & Hughes, T. P. (2002) · Blood · doi:10.1182/blood.v99.9.3472 · Cited by 649
Li, S., Ilaria, R. L., Million, R. P., Daley, G. Q., & Van Etten, R. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1399 · Cited by 501
Self-citationMeng, F., & Lowell, C. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.9.1661 · Cited by 479
Chan, V. W. F., Meng, F., Soriano, P., DeFranco, A. L., & Lowell, C. A. (1997) · Immunity · doi:10.1016/s1074-7613(00)80511-7 · Cited by 451
McLaughlin, J., Chianese, E., & Witte, O. N. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.18.6558 · Cited by 367
Roumiantsev, S., Shah, N. P., Gorre, M. E., Nicoll, J., Brasher, B. B., Sawyers, C. L., & Van Etten, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162140299 · Cited by 253
Self-citationAlternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene
Goga, A., McLaughlin, J., Afar, D. E. H., Saffran, D. C., & Witte, O. N. (1995) · Cell · doi:10.1016/0092-8674(95)90277-5 · Cited by 248
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336
Hoover, R. R., Mahon, F.-X., Melo, J. V., & Daley, G. Q. (2002) · Blood · doi:10.1182/blood.v100.3.1068 · Cited by 241
kat: a high-efficiency retroviral transduction system for primary human T lymphocytes
Finer, M., Dull, T., Qin, L., Farson, D., & Roberts, M. (1994) · Blood · doi:10.1182/blood.v83.1.43.43 · Cited by 224
The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells
Klejman, A. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf562 · Cited by 222
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9
Dash, A. B., Williams, I. R., Kutok, J. L., Tomasson, M. H., Anastasiadou, E., Lindahl, K., Li, S., Van Etten, R. A., Borrow, J., Housman, D., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.102583199 · Cited by 209
Self-citationMolecular mechanisms of transformation by the BCR-ABL oncogene
Sattlermc, M., & Griffin, J. D. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)70013-4 · Cited by 203
Rosée, P. G. L., Corbin, A. S., Stoffregen, E. P., Deininger, M. W., & Druker, B. J. (2002) · PubMed · Cited by 203
Sexl, V., Piekorz, R., Moriggl, R., Rohrer, J., Brown, M. P., Bunting, K. D., Rothammer, K., Roussel, M. F., & Ihle, J. N. (2000) · Blood · doi:10.1182/blood.v96.6.2277 · Cited by 198
Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils
Daigle, I., Yousefi, S., Colonna, M., Green, D. R., & Simon, H.-U. (2002) · Nature Medicine · doi:10.1038/nm0102-61 · Cited by 184
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
Danhauser-riedl, S., Warmuth, M., Druker, B. J., Emmerich, B., & Hallek, M. J. (1996) · PubMed · Cited by 182
Self-citationAutoinhibition of Bcr-Abl through Its SH3 Domain
Smith, K. M., Yacobi, R., & Van Etten, R. A. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00274-0 · Cited by 162
Self-citationPhosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571
Klejman, A., Rushen, L., Morrione, A., Słupianek, A., & Skórski, T. (2002) · Oncogene · doi:10.1038/sj.onc.1205724 · Cited by 160
Wilson, M. B., Schreiner, S. J., Choi, H.-J., Kamens, J., & Smithgall, T. E. (2002) · Oncogene · doi:10.1038/sj.onc.1206008 · Cited by 136
Million, R. P., & Etten, R. A. V. (2000) · Blood · doi:10.1182/blood.v96.2.664 · Cited by 136
Warmuth, M., Simon, N., Mitina, O., Mathes, R., Fabbro, D., Manley, P. W., Buchdunger, E., Forster, K., Moarefi, I., & Hallek, M. J. (2002) · Blood · doi:10.1182/blood-2002-01-0288 · Cited by 134
Self-citationHe, Y., Wertheim, J. A., Xu, L., Miller, J. P., Karnell, F. G., Choi, J. K., Ren, R., & Pear, W. S. (2002) · Blood · doi:10.1182/blood.v99.8.2957 · Cited by 121
Warmuth, M., Bergmann, M., Prieß, A., Häuslmann, K., Emmerich, B., & Hallek, M. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.52.33260 · Cited by 120
Self-citationLionberger, J. M., Wilson, M. B., & Smithgall, T. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000126200 · Cited by 115
Wolff, N. C., & Ilaria, R. L. (2001) · Blood · doi:10.1182/blood.v98.9.2808 · Cited by 106
Li, S., Couvillon, A. D., Brasher, B. B., & Etten, R. A. V. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6793 · Cited by 104
Self-citationRoumiantsev, S. A., de Aos, I. E., Varticovski, L., Ilaria, R. L., & Etten, R. A. V. (2001) · Blood · doi:10.1182/blood.v97.1.4 · Cited by 101
SH2-containing phosphotyrosine phosphatase Syp is a target of p210bcr-abl tyrosine kinase.
Tauchi, T., Feng, G., Shen, R., Song, H., Donner, D. B., Pawson, T. J., & Broxmeyer, H. E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36617-6 · Cited by 84
Cuenco, G. M., & Ren, R. (2001) · Oncogene · doi:10.1038/sj.onc.1205095 · Cited by 79
Li, S., Gillessen, S., Tomasson, M. H., Dranoff, G., Gilliland, D. G., & Etten, R. A. V. (2001) · Blood · doi:10.1182/blood.v97.5.1442 · Cited by 74
Self-citationStudying the pathogenesis of BCR–ABL+ leukemia in mice
Etten, R. A. V. (2002) · Oncogene · doi:10.1038/sj.onc.1206091 · Cited by 56
Yang, W., McKenna, S. D., Jiao, H., Tabrizi, M. H., Lynes, M. A., Shultz, L. D., & Yi, T. (1998) · PubMed · Cited by 21
Cited by
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Self-citationThe development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M., Buchdunger, E., & Druker, B. J. (2005) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,253
Self-citationCardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
Self-citationMechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
Ren, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1567 · Cited by 878
Molecular biology of bcr-abl1–positive chronic myeloid leukemia
Quintás-Cardama, A., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-03-144790 · Cited by 745
Metadata
- Authors
- Hu, Y., Liu, Y., Pelletier, S., Buchdunger, E., Warmuth, M., Fabbro, D., Hallek, M., Van Etten, R. A., & Li, S.
- Venue
- Nature Genetics
- Published
- 2004-04-18
- Volume
- 36
- Issue
- 5
- Pages
- 453-461
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2037154482
- Cited by
- 405
- References
- 39
- FWCI
- 20.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.